UNICREDIT BANK/CALL/MODERNA/150/0.1/18.09.24 | Market Closed - BOERSE MUENCHEN 03:41:44 2024-06-27 pm EDT | ||
| 0.42 EUR | -10.64% |
|
| Current month | -68.42% | ||
| 1 month | -84.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.42 | -10.64% |
| 24-06-26 | 0.47 | -46.59% |
| 24-06-25 | 0.88 | +1.15% |
| 24-06-24 | 0.87 | +4.82% |
| 24-06-21 | 0.83 | -1.19% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD03ZD |
| ISIN | DE000HD03ZD9 |
| Date issued | 2023-10-23 |
| Strike | 150 $ |
| Maturity | 2024-09-18 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.92 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.01 € |
| Spread % | 2.44% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
